<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866645</url>
  </required_header>
  <id_info>
    <org_study_id>2004L03556</org_study_id>
    <secondary_id>SMHC-100</secondary_id>
    <nct_id>NCT00866645</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia</brief_title>
  <official_title>A Randomized Blind Parallel Intramuscular Haloperidol-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Intramuscular Levosulpiride in the Treatment of Chinese Patients With Agitation Of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Hotmed Sciences Co.,LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of Intramuscular
      Levosulpiride in the treatment of Chinese patients with Agitation Of Schizophrenia compared
      with Intramuscular Haloperidol by evaluating the change of PANSS-EC total scores at end of
      study (72 hours after first dosing) from baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary Outcome Measures:

      To evaluate the change of Agitation Calmness Evaluation Scale(ACES), Clinical Global
      Impression(CGI, including CGI-S and CGI-I),PANSS total scores,Brief Psychiatric Rating
      Scale(BPRS) total scores and every item of PANSS-EC from baseline to the end of study (Time
      Frame: 72 hours) [ Designated as safety issue: No ]

      To evaluate the change of patients' main complain, physical examination, lab and ECG tests,
      AE、Rating Scale for Extrapyramidal Side Effect(RSESE) and Barnes Akathisia Scale(BAS)from
      baseline to the end of study (Time Frame: 72 hours) [ Designated as safety issue: Yes ]
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of PANSS-EC total scores</measure>
    <time_frame>from baseline to the end of study(72 hours after first dosing)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of Agitation Calmness Evaluation Scale(ACES)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of Clinical Global Impression(CGI, including CGI-S and CGI-I)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of PANSS total scores</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Brief Psychiatric Rating Scale(BPRS) total scores</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of every item of PANSS-EC</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Rating Scale for Extrapyramidal Side Effect(RSESE)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Barnes Akathisia Scale(BAS)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular Levosulpiride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular Haloperidol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Haloperidol</intervention_name>
    <description>1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Intramuscular Haloperidol parenteral solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Levosulpiride</intervention_name>
    <description>2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Intramuscular Levosulpiride parenteral solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Chinese inpatients(are required to stay at hospital during the study)
             aged 18-65 years

          -  Patients meeting the DSM-IV criteria for schizophrenia or schizophreniform psychosis

          -  Agitated with a minimum total score of ≧ 15 on the five items of the PANSS-EC and at
             least one individual item score of ≧ 5 or two item score of ≧ 4 using the 1-7 scoring
             system

          -  ACES≤3

          -  Written informed consent provided by patients' legal representative

        Exclusion Criteria:

          -  Investigator and his/her relatives

          -  Participation in another drug trial within 3 months prior enrolment into this study

          -  Female patients during their pregnant and lactation period

          -  Any currently severe unstable medical illness or disease would affect assessment for
             this study, including epilepsy, angle closure glaucoma, disease of liver, kidney,
             gastrointestinal tract, respiratory system, cardiovascular system(including Ischemic
             Heart Disease), endocrine system, nervous system, immune or hematological system etc.

          -  A significantly clinical abnormal value in ECG or lab results,ALT and AST values in
             the liver function test exceeding two times of the upper limits of normal values, urea
             nitrogen value arising up to 1.2 times of the upper limits of normal values,
             creatinine or serum potassium exceeding normal values

          -  With a family history of sudden death

          -  Meet the DSM-IV criteria for substance abuse within 1 year prior enrolment

          -  Regularly use antipsychotics(clozapine within 90 days), antidepressants, mood
             stabilizers, anti-epileptics or prolonged-action preparations within 2 weeks prior
             enrolment

          -  Use of Electroconvulsive therapy within 30 days prior enrolment

          -  Systematically use of sulpiride, levosulpiride or haloperidol therapy within 30 days
             prior enrolment

          -  History of or current neuroleptic malignant syndrome, severe EPS, significant tardive
             dyskinesia

          -  Severe suicide attempt

          -  Known hypersensitivity to sulpiride, levosulpiride or haloperidol, or history of
             severe drug hypersensitivity or hypersensitivity to more than 2 drugs

          -  Use of psychotropics(except permitted drugs) within 12 hours prior enrolment

          -  Known lack of efficacy to levosulpiride or haloperidol by formal treatment before

          -  Organic mental disorders, including Mental retardation

          -  History of psychosurgery treatment

          -  Patients can not comply with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Drug Clinical Trial Office, Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei Mental Health Center</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affilliated Hospital Of Kunming Medical College</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>GU, Niufan</name_title>
    <organization>Shanghai Mental Health Center</organization>
  </responsible_party>
  <keyword>Agitation</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Randomized</keyword>
  <keyword>Blind</keyword>
  <keyword>Parallel</keyword>
  <keyword>Intramuscular Haloperidol</keyword>
  <keyword>Controlled</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Intramuscular Levosulpiride</keyword>
  <keyword>Chinese</keyword>
  <keyword>PANSS-EC</keyword>
  <keyword>ACES</keyword>
  <keyword>CGI</keyword>
  <keyword>BPRS</keyword>
  <keyword>PANSS</keyword>
  <keyword>RSESE</keyword>
  <keyword>BAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

